Tdap & Biomarkers of Alzheimer's Disease

Status Not yet recruiting

Clinical Trial Summary

Recently, the Tdap (tetanus toxoid, reduced diphtheria toxoid and acellular pertussis) vaccination was added to the list of immunizations associated with lower incidence of dementia. Plasma-based biomarkers for AD are a welcome alternative to expensive and invasive testing for Alzheimer's; these biomarkers include assessment of amyloid and tau and neurofilament light protein that assesses non-specific neurodegeneration. The investigators will test for these biomarkers, as well as some immune parameters, administer Tdap then repeat the blood tests in six months.

Clinical Trial Description

A growing number of studies have consistently shown reduced incident risk of dementia associated with a variety of vaccinations. Most recently, data probes of medical claims from two large and disparate databases showed that vaccination for tetanus, diphtheria and pertussis (Tdap) was associated with a 42% decrease in dementia. Adult vaccination coverage remains low for most routinely recommended vaccines, including Tdap. This study will screen and qualify participants who do not meet the recommended frequency interval for Tdap vaccination. Participants will have consented to a review of their medical history (including vaccination history), a neurocognitive test and a battery of blood tests. Included in the blood testing will be plasma-based testing for amyloid, tau and neurofilament light protein. The study will be considered a pilot study; it will be an open-label trial. All participants will receive a single dose of the Tdap vaccine. Nine months after vaccination, participants will repeat the pre-vaccine blood tests. Primary objective will be the assessment of change in the Alzheimer's disease (AD) biomarkers. Bordetella pertussis (B. pertussis), the bacterium that causes whopping cough, is one of the targets of the Tdap vaccine. B. pertussis is a hypothesized infectious trigger of Alzheimer's disease (AD). A secondary objective of the study will be determination of present and past infection by B. pertussis via IgG testing as well as PCR of nasal swab and how this may relate to the Alzheimer biomarker responses to Tdap vaccination. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05183516
Study type	Interventional
Source	Mindful Diagnostics and Therapeutics, LLC
Contact	Coad T Dow, MD
Phone	715-577-5656
Email	ctomdow@gmail.com
Status	Not yet recruiting
Phase	Phase 1/Phase 2
Start date	May 1, 2023
Completion date	March 31, 2024

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT05407272` - Explore the Sharing Model Intervene to Improve the Knowledge, Attitudes, Service Intentions and Service Start-up Effects of the Eight Major Non-cancer Disease End-stage Caregivers on Well-being and Palliative Care	N/A
Completed	`NCT02958930` - Safety and Efficacy of Transcranial Electromagnetic Treatment Against Alzheimer's Disease	N/A
Completed	`NCT04449926` - BCG and Plasma Amyloid in Non-Demented Adults	Phase 2
Recruiting	`NCT06203106` - NYSCF Scientific Discovery Biobank
Active, not recruiting	`NCT03661034` - Study of Tolerability, Safety and Efficacy of Sensory Stimulation at Multiple Dose Levels to Improve Brain Function (Etude Study)	N/A
Recruiting	`NCT04263194` - Network-based rTMS in Alzheimer's Disease	N/A
Recruiting	`NCT04100889` - A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Alzheimer's Disease
Completed	`NCT02187276` - The Predictive Factors of Good Clinical Response to Cholinesterase Inhibitors in Alzheimer Disease and Mixed Dementia	N/A
Recruiting	`NCT04680013` - Genetic Studies in Familial Dementia
Recruiting	`NCT04270474` - Reducing Risk of Dementia Through Deprescribing	N/A
Not yet recruiting	`NCT06448403` - Multimodal Assesment of Alzheimer Patients
Enrolling by invitation	`NCT06078891` - Does BCG Vaccination Reduce Biomarkers of Alzheimer's Disease?	Early Phase 1
Recruiting	`NCT05138848` - Time-in-bed Restriction in Older Adults With Sleep Difficulties With and Without Risk for Alzheimer's Disease	N/A
Withdrawn	`NCT03149380` - Effectiveness of Alzheimer's Universe (Www.AlzU.Org) on Knowledge and Behavior	N/A
Recruiting	`NCT03653156` - China Cognition and Aging Study
Completed	`NCT03300726` - Synaptic Injury and Functional Connectivity in Alzheimer's Disease
Recruiting	`NCT01773915` - New Proteins in Body Fluids as Potential Biomarker for Alzheimer's Disease: a Pilot Study	N/A
Recruiting	`NCT05655195` - Chronic Treatment of Alzheimer's Disease by Gamma Light and Sound Therapy	N/A
Recruiting	`NCT05637801` - A Pivotal Study of Sensory Stimulation in Alzheimer's Disease (Hope Study, CA-0011)	N/A
Recruiting	`NCT03153371` - Early-onset Alzheimer's Disease Phenotypes: Neuropsychology and Neural Networks

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Tdap and Biomarkers of Alzheimer's Disease

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms